Reviews of Testosterone TherapyPrepared by Harvard Health Publications' editors, this page report describes the causes and treatment of prostate diseases and provides practical advice for coping with troubling side effects. Get weekly health information and advice from testosterone therapy user reviews experts at Harvard Medical School. Learn more about this site in a welcome video from Dr. Marc Garnick, editor in chief. Testosrerone could be said propionate and anavar cycle results testosterone is what makes men, men. It gives testosterone therapy user reviews their characteristic deep voices, large muscles, and facial and body hair, distinguishing them from women. It stimulates the growth of the genitals at puberty, plays a role in sperm production, fuels libido, and contributes to normal erections.
Effects of 6-year Long-Term Testosterone Replacement Therapy (TRT) in Patients with ‘‘Diabesity’’
March 6th FDA approved Aveed for treatment of male hypogonadism, aka testosterone deficiency. In Europe, testosterone undecanoate under the name Nebido has a long successful TRT track record for treatment of testosterone deficiency and its consequences especially obesity, the metabolic syndrome and diabetes. In contrast to shorter acting forms of testosterone e. Five days after the FDA approval a notable and impressive 6-year long TRT study was published, confirming the health benefits of TRT that have previously been found in shorter term studies… More and more studies are showing that testosterone deficiency contributes to development of obesity both general and abdominal , insulin resistance, metabolic syndrome, type-2 diabetes and muscle loss.
Several recent 5-year long-term studies reported that TRT results in marked and significant weight fat loss, reduction in waist circumference and BMI, as well as improvements in blood cholesterol parameters and reductions in fasting glucose, HbA1c, CRP in inflammatory marker and liver enzymes.
The longest study reported to date was conducted by a research group in Germany led by Dr Farid Saad, one of the most prominent worldwide leaders in the field of TRT research. This study was published March 11th, in the International Journal of Endocrinology. Subjects were obese hypogonadal men with type-2 diabetes, aged between 41 and 73 years. All men received treatment with testosterone undecanoate mg Nebido, Bayer Pharma, Berlin, Germany , administered at baseline and at 6 weeks, and thereafter every 12 weeks for up to 72 months.
Waist circumference WC was measured midpoint between the iliac crest top of the hip bone and the lowest rib. All subjects were followed for at least one year, for at least two years, for three years, for four years, for five years, and 69 for six years. Figure 1 demonstrates the measured reduction in waist circumference subsequent to testosterone therapy in obese diabetic men.
Waist circumference dropped from an average from The reduction in waist circumference was statistically significant at the end of each year compared to the previous year over the first five years, even at the end of six compared to five years. Figure 2 shows the effects of TRT on body weight over the course of 6 years of therapy. Body weight decreased from an average of lb minimum lb, maximum lb [ kg minimum 87 kg, maximum kg to lb minimum lb, maximum lb [97 kg min 80, max ] with a mean loss of This decrease in body weight was statistically significant at the end of each year compared to the previous year over the first five years, even at the end of six compared to five years.
A marked and significant decrease in percentage body weight was noted over the course of testosterone therapy. After one year, patients had lost 3. These successive yearly changes were statistically significant compared with baseline.
There was a significant gradual decrease in fasting blood glucose from The decrease was significant after one year, further declined after two years non-significant compared to level after year 1 , and then reached a plateau with another slight but statistically significant decrease at five years compared to four years. Over the course of 6 year testosterone treatment, fasting blood glucose decreased by The decrease in fasting blood glucose was accompanied by a marked decrease in HbA1c from 8.
The decrease in HbA1c was progressive and statistically significant after one year, between two years and one year, between three and two years, between four and three years, and between five and four years and approached significance between six and five years. The mean changes in lipid profiles were gradual and progressive and were significant at each year when compared to baseline levels, reaching plateaus between three and four years.
The ratio of total cholesterol to HDL cholesterol improved from 6 to 3. These changes reached a plateau after three years with further slight but not statistically significant decreases. In addition, testosterone treatment significantly reduced blood pressure, CRP an inflammatory marker and levels of the liver enzymes aspartate transaminase AST and alanine transaminase ALT , suggesting a reduction in liver fat content, a reduced inflammatory response, and improvement in liver function.
It was found that obese diabetic men in the higher testosterone category responded to testosterone treatment equally well as those with lower baseline testosterone levels.
The study authors concluded that long-term TRT for up to 6 years results in significant and sustained improvements in weight, type-2 diabetes, and other cardiometabolic risk factors in testosterone deficient obese, diabetic.
Several of results from the above outlined 6-year long TRT study deserve special mention: First, this 6-year long study clearly demonstrates that TRT confers long term effects for the duration of treatment.
PSA and prostate volume initially rises marginally, but it reaches a plateau at around 12 month further increase should be related to aging rather than therapy. Prostate growth is extremely sensitive to variations in androgen concentrations at very low concentrations, but becomes insensitive to changes in androgen concentrations at higher levels. Second, TRT with testosterone undecanoate mg at baseline, 6 wk and every 12 wk thereafter restored physiological testosterone levels within the first 12 months, and testosterone levels were maintained at this dosage regimen throughout the entire 6-year period.
It should be noted that different testosterone preparations e. Third, over the course of 6 years, TRT markedly and significantly reduced total cholesterol and LDL levels, and this reduction was very pronounced and sustained over the entire 6-year period of testosterone treatment.
Moreover, the ratio of total cholesterol to HDL cholesterol dropped from over 6 to below 3. Fourth, another important observation in this study was the marked and significant reduction in triglycerides blood fats in response to TRT. Since intra-abdominal visceral fat storage is driven by accumulation of triglycerides, this could help explain the reduction in waist circumference. In addition, the great reduction in triglycerides, especially when combined with the elevation in HDL, is an indication of an increased LDL particle size i.
Sixth, it is notable that men with both very low and borderline low total testosterone levels responded equally well to this 6-year long-term testosterone treatment. Finally, this study clearly shows that different outcomes plateau at different time points. Importantly and interestingly, the reductions in waist circumference and body weight and percentage change in body weight were statistically significant at the end of each year compared to the previous year over the first five years, and even at the end of the sixth year compared to fifth year.
This is an unusual and remarkable finding, as obesity interventions both drugs and lifestyle changes commonly are most effective the first year, and thereafter progressively lose their efficacy. Accessed March 12th, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: The journal of sexual medicine.
Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: International journal of clinical practice. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in aging men with symptomatic testosterone deficiency: Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months.
Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate Nebido. World journal of urology. The efficacy and safety of testosterone undecanoate Nebido R in testosterone deficiency syndrome in Korean: Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate mg IM—Nebido.
Endocrine and metabolic effects of experimental obesity in man. Recent progress in hormone research. Overweight and obesity and weight change in middle aged men: Journal of epidemiology and community health.
Abdominal obesity and the metabolic syndrome: Arteriosclerosis, thrombosis, and vascular biology. The perils of portliness: Risk of type 2 diabetes according to traditional and emerging anthropometric indices in Spain, a Mediterranean country with high prevalence of obesity: Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: American journal of epidemiology.
Diabetes, metabolic syndrome and obesity: Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. American journal of physiology Endocrinology and metabolism. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Lowered testosterone in male obesity: Mechanisms, morbidity and management.
Asian journal of andrology. Relationship between low free testosterone levels and loss of muscle mass. Higher testosterone levels are associated with less loss of lean body mass in older men. The Journal of clinical endocrinology and metabolism. Serum free testosterone and metabolic syndrome in Japanese men. Androgen therapy in men with testosterone deficiency: Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.
Journal of the American Geriatrics Society. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: Mechanical muscle function and lean body mass during supervised strength training and testosterone therapy in aging men with low-normal testosterone levels. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men.
Testosterone and growth hormone improve body composition and muscle performance in older men.